Lysogene Enters into a Loan Agreement of €15 million with the European Investment Bank (EIB)
Retrieved on:
Friday, December 24, 2021
Biotechnology, Genetics, Health, Kepler, Sarepta Therapeutics, European Investment Bank, Fragile, Sale, Autism, Lists of diseases, MPS, Exercise, CNS, European Agricultural Guarantee Fund, Financial Services and Markets Authority (Belgium), Investment, BPI, Achievement, Forward-looking statement, COVID-19, Central nervous system, Fragile X syndrome, EIB, Union, History, Climate, Company, LYS, Therapy, Research, Adaptive clinical trial, GM1, Clinical trial, Parity, Vaccine, Partnership, Pharmaceutical industry, EU, GM1 gangliosidoses, the European Investment Bank (EIB), Lysogene, THE EUROPEAN INVESTMENT BANK (EIB), LYSOGENE
Lysogene (FR0013233475 LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has entered into a 15 million loan agreement with the European Investment Bank to accelerate the development of its gene therapy platform.
Key Points:
- Lysogene (FR0013233475 LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has entered into a 15 million loan agreement with the European Investment Bank to accelerate the development of its gene therapy platform.
- Lysogene will receive the EIB loan in three tranches including a first tranche of 3 million that can be unconditionally drawn down and two other tranches of respectively 5 million and 7 million available upon completion of pre-defined milestones.
- With the 4.3 million BPI non-dilutive announced in November, this brings total funding agreements to nearly 20 million.
- The loan is supplemented by an agreement to issue warrants to the EIB, whose number varies according to the tranche and Lysogenes share price.